Experian share price: company announces healthcare platform integration

on Dec 20, 2013
Updated: Oct 21, 2019
Listen

iNVEZZ.com, Friday, December 20: Experian Plc (LON:EXPN) has integrated its identity proofing and risk-based authentication platform with a patient portal to enable healthcare providers to verify the identity of patients.

Experian’s share price, which has added about nine percent this year, is just under 0.4 percent up in London trading today.
**Experian unveils healthcare platform integration**
Experian said yesterday in a statement that it had integrated its Precise IDSM platform for healthcare portals with the patient portal MyChart of Wisconsin-based healthcare software provider Epic. The purpose of the integrated platform is to enable healthcare providers to authenticate, validate and risk-assess patient identities prior to accessing medical information online.

Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.

Precise ID for healthcare portals combines Experian’s identity proofing and risk-based authentication technology with data assets and analytics to help healthcare organisations verify patient identities. Prior to accessing medical information online, patients and authorised users can be authenticated via a combination of real-time questions.
Dan Buell, general manager of Experian Healthcare, commented in the statement: “The integration of Precise ID for healthcare portals with Epic’s application will instil a level of trust and confidence with patients that their medical and personal information remains secure.”

Experian has been trying to boost its presence in the US healthcare market which it first entered five years ago. Last month, the company announced that it would acquire US Healthcare data company Passport Health Communications for $850 million (£528 million). (Experian’s share price slides 6% after $850 million US deal)
**Half-year results update**

Experian updated markets on its half-year performance in November, posting pre-tax profit from continuing operations of $480 million for the six-month period ended September 30, 2013, up from $73 million last year. Revenue from continuing businesses climbed six percent to $2.3 billion while earnings per share jumped to $0.34 from $0.07 in the prior-year period.

“For the second half, we expect organic revenue growth to be in a similar range as in the first half,” Experian’s CEO Don Robert said in a statement. Robert added that the group expected to convert at least 90 percent of its earnings before interest and tax (EBIT) into operating cash. Experian posted total EBIT from continuing operations of $608 million, up three percent at actual exchange rates.
**Analysts on Experian**
As reported by Analyst Ratings Network, on Tuesday Jefferies Group cut its price target on Experian from 1,200p to 1,090p while maintaining its ‘hold’ rating on the stock. Credit Suisse this week reiterated their ‘outperform’ rating on the Dublin-based information services provider and kept their price target of 1,390p.
**As of 14:56 UTC, buy Experian shares at 1,092.00p.**
**As of 14:56 UTC, sell Experian shares at 1,091.00p.**

Trade stocks with Hargreaves Lansdown from £5.95 per deal.
Prices can go up and down meaning you can get back less than you invest. This is not advice. Dealing services provided by Hargreaves Lansdown.

Ad

Want easy-to-follow crypto, forex & stock trading signals? Make trading simple by copying our team of pro-traders. Consistent results. Sign-up today at Invezz Signals.

Learn more
Health & pharma Services Stock Market